Italia markets closed

ACADIA Pharmaceuticals Inc. (0A4W.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
15,12-0,34 (-2,19%)
Alla chiusura: 05:37PM BST

ACADIA Pharmaceuticals Inc.

12830 El Camino Real
Suite 400
San Diego, CA 92130
United States
858 558 2871
https://www.acadia.com

Settore/i
Settore
Impiegati a tempo pieno610

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Stephen R. Davis J.D.President, CEO & Director1,77M927,35k1961
Mr. Mark C. SchneyerExecutive VP & CFO821,81kN/D1974
Mr. Brendan P. TeehanExecutive VP, COO & Head of Commercial849,2kN/D1969
Mr. James K. KiharaVP, Chief Accounting Officer & Corporate ControllerN/DN/D1981
Mr. Benir RuanoSenior Vice President of Technical Development & OperationsN/DN/DN/D
Mr. Albert S. KildaniSenior Vice President of Investor Relations & Corporate CommunicationsN/DN/DN/D
Ms. Jennifer J. Rhodes J.D.Executive VP, Chief Legal Officer & SecretaryN/DN/D1970
Ms. Julie FisherSenior Vice President of Marketing & Commercial StrategyN/DN/DN/D
Ms. Holly ValdiviezSenior VP & Head of SalesN/DN/DN/D
Mr. Rob AcklesSenior VP & Chief People OfficerN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Governance aziendale

L'ISS Governance QualityScore di ACADIA Pharmaceuticals Inc. al 1 giugno 2024 è 6. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 4; diritti degli azionisti: 8; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.